● Analysis Background
On April 15, 2025, Johnson & Johnson reported its financial results for the first quarter of 2025. This report provides a comprehensive analysis of the company's performance, strategic developments, and investment considerations based on the latest data.
● Company Overview
Johnson & Johnson is a leading global healthcare company headquartered in New Brunswick, New Jersey. Founded in 1886, the company operates through two primary segments: Innovative Medicine and MedTech. Johnson & Johnson is known for its commitment to research and development, delivering a broad range of products and services in the healthcare sector.
● Business Segments and Performance Structure
- Innovative Medicine: This segment focuses on pharmaceutical products across various therapeutic areas, including oncology, immunology, neuroscience, and infectious diseases. In Q1 2025, the segment reported revenue of $13.87 billion, driven by strong sales of Darzalex and Spravato.
- MedTech: This segment includes a wide range of medical devices and technologies. In Q1 2025, MedTech revenue was $8.02 billion, reflecting growth in cardiovascular and wound-closure products, partially offset by challenges in orthopedics.
● Q1 2025 Financial Summary
| Metric | Q1 2025 | Q1 2024 | Year-over-Year Change |
|---|---|---|---|
| Total Revenue | $21.89B | $21.38B | +2.4% |
| Net Income | $10.999B | $3.255B | +237.9% |
| EPS (Diluted) | $4.54 | $1.34 | +238.8% |
| Adjusted EPS (Non-GAAP) | $2.77 | $2.71 | +2.2% |
| Free Cash Flo |